Opinion|Videos|April 28, 2025
Exciting Future Horizons for CAR T in MM and Take-Home Messages
Author(s)Surbhi Sidana, MD, Peter Voorhees, MD
Experts share their closing thoughts and key take-home messages from the discussion, summarizing important insights and takeaways for enhancing patient care and treatment strategies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Before we end, I would like to get your closing thoughts or key take-home messages from today.
Advertisement
Related to this article
Estelamari Rodriguez, MD, MPH, discusses the rationale, design, and practice implications of the phase 3 RELATIVITY-1093 trial in nonsquamous NSCLC.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
A New England Journal of Medicine report describes complete hepatoblastoma regression in a 3-year-old treated with a novel immunotherapy.
Plinabulin plus docetaxel received fast track designation for pretreated nonsquamous NSCLC without actionable genomic alterations.
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
Denosumab-adet (Degevma) is FDA approved as an Xgeva biosimilar for SRE prevention in myeloma and bone metastases, giant cell tumor of bone, and HCM.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss individualized treatment and strategic sequencing in HER2-mutated NSCLC.
Researchers at Wake Forest University School of Medicine identified a protein that may help breast cancer spread to the brain and evade immune defenses.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
2
CNS Control and Daily Tolerability Guide Treatment Sequencing in HER2-Mutated NSCLC
3
Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Cancer
4
Tabelecleucel BLA Is Resubmitted to FDA for EBV+ Post-Transplant Lymphoproliferative Disease
5